On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Jiangsu Simcere Pharmaceutical Co., Ltd.

29 YRS

Jiangsu, China

CNY 568.8 Million

219780 m²

Over 1000 people

Main Products: Posaconazole / Diosmectite / Zanamivir / Palonosetron Hydrochloride / Pemetrexed Disodium / Bendamustine HCl / Palbociclib / Cabozantinib Malate / Ibrutinib / Edoxaban(Tosylate Monohydrate) / Bedaquiline Fumarate / Apremilast

Jiangsu, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Palbociclib / CAS 571190-30-2

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Palbociclib

Product introduction:

Pabcilib is an inhibitor of cyclin dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream of the signal pathway leading to cell proliferation. In vitro, pabcilib estrogen receptor (ER) - positive breast cancer cell lines reduce cell proliferation by blocking the progression of cells from G1 to S phase of cell cycle. Compared with each drug alone, the combined treatment of pabcilib and anti estrogen resulted in decreased phosphorylation of retinoblastoma protein (RB), decreased E2F expression and signal and prevented increased growth. In vitro treatment of ER positive breast cancer cell lines with pabcilib and anti estrogen resulted in increased cell senescence, which lasted up to 6 days after drug removal.

Synonymous：	Pabcilib
CAS：	571190-30-2
Molecular Formula：	C₂₄H₂₉N₇O₂
Molecular Weight：	447.53
Appearance：	White to beige powder
Storage：	Closed storage at room temperature
Category：	Tumor drugs

Typical Properties

Pabcicilib is an inhibitor of cyclin dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream signaling pathways leading to cell proliferation. In vitro, the proliferation of ER positive breast cancer cells was inhibited by blocking the progression from G1 to S phase. Compared with the treatment of each drug alone, the combination of pabacib and anti estrogen resulted in decreased phosphorylation of retinoblastoma protein (RB), decreased E2F expression and signal, and prevented growth. In vitro treatment of ER positive breast cancer cell lines with combination of pabacib and anti estrogen resulted in increased cell senescence, which lasted up to 6 days after drug removal.

CAS No.

571190-30-2

Formula

C24H29N7O2

Molecular Mass

447.53

Exact Mass

447.23800

PSA

105.04000

Logp

3.43260

IUPAC

6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one

SMILES

CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C

Matter Classification

organic

GET SAMPLE